CPT-I I sensitivity in relation to the expression of P1 70-glycoprotein and multidrug resistance-associated protein
1998

CPT-11 Sensitivity and Drug Resistance in Cancer Cells

publication Evidence: moderate

Author Information

Author(s): WJM Jansen, TM Hulscher, J van Ark-Otte, G Giaccone, HM Pinedo, E Boven

Primary Institution: Academic Hospital Vrije Universiteit

Hypothesis

The study investigates the relationship between P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) expression and sensitivity to CPT-11 in cancer cells.

Conclusion

P-gp-positive cells show low cross-resistance against CPT-11 and SN-38, while MRP does not significantly affect sensitivity to these drugs.

Supporting Evidence

  • P-gp-positive sublines showed slight cross-resistance against CPT-11.
  • BIBW22BS was the most effective modulator in reversing resistance against CPT-11.
  • 2780AD xenografts were slightly less sensitive to CPT-11 than parent tumors.
  • MRP-positive subline GLC4/ADR was cross-resistant against carboxylesterase-activated CPT-11.

Takeaway

This study looks at how certain proteins in cancer cells affect their ability to resist a specific cancer drug. It finds that one protein, P-gp, doesn't make the cells very resistant to the drug.

Methodology

The study compared the activity of CPT-11 and its metabolite SN-38 in various cancer cell lines and their resistant sublines, using in vitro and in vivo experiments.

Limitations

The study primarily focuses on specific cell lines and may not fully represent the complexity of drug resistance in all cancer types.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication